Best practices in bioassay development to support registration of biopharmaceuticals.

John R White, Marla Abodeely, Sammina Ahmed, Gaël Debauve, Evan Johnson, Debra M Meyer,Ned M Mozier, Matthias Naumer, Alessandra Pepe, Isam Qahwash, Edward Rocnik, Jeffrey G Smith, Elaine Se Stokes, Jeffrey J Talbot, Pin Yee Wong

BIOTECHNIQUES(2019)

引用 17|浏览6
暂无评分
摘要
Biological activity is a critical quality attribute for biopharmaceuticals, which is accurately measured using an appropriate relative potency bioassay. Developing a bioassay is a complex, rigorous undertaking that needs to address several challenges including modelling all of the mechanisms of action associated with the biotherapeutic. Bioassay development is also an exciting and fast evolving field, not only from a scientific, medical and technological point of view, but also in terms of statistical approaches and regulatory expectations. This has led to an industry-wide discussion on the most appropriate ways to develop, validate and control the bioassays throughout the drug lifecycle.
更多
查看译文
关键词
best practice,bioassay,biologicals,control,development,outlier,plate design,potency,replication strategy,statistics,similarity
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要